EUCTR2007-003462-18-ES进行中（未招募）1 期
Estudio pivotal para determinar la eficacia y seguridad de AP23573 administrado como tratamiento de mantenimiento a pacientes con sarcoma metastásico óseo o de partes blandas.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 675
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Documented histologic diagnosis of soft-tissue or bone sarcoma that has metastasized, with the exception of certain histopathologic subtypes of sarcomas recognized by experts to derive no benefit from conventional chemotherapies or with distinctly different natural histories. See Attachment G for a list of excluded sarcoma sub-types.
- •2. Ongoing complete response, partial response or stable disease as defined by RECIST guidelines after a minimum of 4 cycles (and maximum of 12 months) of any one of 1st, 2nd or 3rd line of prior cytotoxic chemotherapy for metastatic disease.
- •3. Disease status (SD or better response) confirmed by a central review of the most recent 2 consecutive radiological evaluations (e.g., CT or MRI scans) obtained a minimum of 6 and a maximum of 10 weeks apart.
- •4. Patients with partial response or stable disease at study entry must have least one measurable or evaluable lesion as defined by RECIST guidelines (see protocol Attachment D)
- •5. Patients with metastatic bone sarcoma must have at least one measurable visceral lesion or have achieved a complete response of visceral metastasis.
- •6. ECOG performance status of 0 or 1 (see protocol Attachment A)
- •7. Male or female patients = 13 years of age (patients 13-17 years of age must weigh at least 100lbs. (45.4 kg)). In regions where applicable local law prohibits enrollment of patients <18 years of age, only patients =18 years of age will be eligible.
- •8. Patients must have normal organ and marrow function as defined below:
- •leukocytes = 3,000/µL
- •absolute neutrophil count = 1,500/µL
- •platelets = 100,000/µL
- •total bilirubin below institutional upper limit of normal (unless patient has Gilbert’s disease in which case =1.5 x ULN)
- •AST(SGOT)/ALT(SGPT) = 2.5 X institutional upper limit of normal (or = 5 x ULN if liver metastases are present)
- •creatinine =1.5 X ULN for the institution (or calculated creatinine clearance = 50 mL/min/1.73 m2)
- •9. Serum cholesterol = 350 mg/dL and triglycerides = 400 mg/dL
- •10. Male and female patients who are not surgically sterile or postmenopausal must agree to use reliable methods of birth control from time of screening until 30 days after the last dose of the study drug
- •11. Able to understand and willing to sign a written informed consent document
- •12. Completed 1st, 2nd or 3rd line chemotherapy and have received last dose = 3 weeks prior to randomization
- •13. Randomization and treatment to begin = 8 weeks following previous treatment
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Women who are pregnant or lactating
- •2. Presence of known or active brain or CNS metastases
- •3. Prior therapy with rapamycin or rapamycin analogs, including AP23573
- •4. Ongoing toxicity associated with prior anticancer therapy = Grade 2 (excluding alopecia) according NCI common terminology criteria
- •5. Another primary malignancy within the past three years (except for non-melanoma skin cancer and cervical carcinoma in situ)
- •6. Known Grade 3 or 4 hypersensitivity to macrolide antibiotics (e.g., clarithromycin, erythromycin, azithromycin)
- •7. Concomitant treatment with medications that induce or inhibit CYP3A. Patients should be off these medications = 2 weeks prior to the first dose of AP23573
- •8. Significant uncontrolled cardiovascular disease
- •9. Active infection requiring systemic therapy
- •10. Known HIV infection
- •11. Concurrent treatment with immunosuppressive agents other than prescribed corticosteroids at stable doses for = 2 weeks prior to first planned dose of study drug
- •12. Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to the first dose of study drug (with the exception of minor procedures, e.g., central venous access port placement)
- •13. Presence of any life-threatening illness or organ system dysfunction which, in the option of the Investigator, would either compromise the patient’s safety or interfere with evaluating the safety of the study drug
研究者
相似试验
进行中（未招募）
1 期
Etude pilote, multicentrique, évaluant l’efficacité d’un traitement anti VHC optimisé (induction par 360µg/S de PegIFN-alpha 2a + 18mg/kg/j de RBV pendant 6 mois puis en fonction de la réponse virologique à S12, allongement jusqu'à S72 de la bithérapie anti VHC, avec mesures d'accompagnement) sur la réponse virologique soutenue chez des patients VHC de génotype 1 et 4, non répondeurs et co-infectés par le VIH. - ETOCCet essai vise à étudier la réponse à un re-traitement optimisé de l’hépatite C chez des patients co-infectés VIH-VHC (génotype 1 et 4), non répondeurs aux premiers traitements pour le VHC.MedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CMedDRA version: 9.1Level: LLTClassification code 10001509Term: AIDSEUCTR2008-000859-10-FRANRS
招募中
3 期
A Multicentre, Randomised, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus ErythematosusSystemic Lupus ErythematosusJPRN-jRCT2071210076Hibi Kazushige36
招募中
Unknown
Prospective Study to Identify Efficacy, Safety, and Predictors of Tezepelumab in Severe Asthmaasthma, bronchial asthmaJPRN-UMIN000049566Japanese Red Cross Medical Center30
进行中（未招募）
不适用
Etude de cohorte évaluant l'efficacité cliique, la tolérance et l'immunogénicité à la vaccination antigrippale pandémique chez les patients atteints de mucoviscidose et, le cas échéant, l'expression clinique de la grippe A (H1N1) et les facteurs associés à la survenue de formes sévères dans cette population. - Etude MUCOFpatients atteints de mucoviscidoseMedDRA version: 12.0Level: LLTClassification code 10011762Term: Cystic fibrosisEUCTR2009-016662-90-FRInserm
尚未招募
2 期
Effectiveness of Prescribed step up exercise program upon functional status and anxiety among Coronary artery bypass surgery patientsCTRI/2024/05/067443Manju G